←Back to list

Syntax Bio

Programming new cell therapies using CRISPR-based technology.
Programming new cell therapies using CRISPR-based technology. Headquartered in Chicago, IL. Raised $14.4M in Series A funding in June 2026 led by Astellas Venture Management.
Biotechnology 📍 Chicago, IL Founded 2026
Current Valuation
Private
PRIVATE

IPO Outlookprivate

Is Syntax Bio going public?
No. Syntax Bio is private and has not filed to go public. There is no S-1 on file.
What is Syntax Bio's valuation in 2026?
No confirmed valuation is on record for Syntax Bio. The roster shows funding and investors where they are public; it does not estimate a mark.
Has Syntax Bio filed an S-1?
No public S-1 is on file for Syntax Bio.
Who are Syntax Bio's investors?
Syntax Bio's investors include Astellas Venture Management, Illumina Ventures, DCVC Bio, Civilization Ventures, EGB Capital, Mansueto Office and 6 more.
How much has Syntax Bio raised?
Syntax Bio has raised $25M in total across 1 disclosed round, most recently a Series A of $14.4M in Jun 2026.
Is Syntax Bio publicly traded — can you buy Syntax Bio stock?
No. Syntax Bio is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Syntax Bio on its Pre-IPO Access Desk.
How to actually get exposure to Syntax Bio →
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.

Company Profile

CEO
John Craighead
Founded
2026
HQ
Chicago, IL
Total Raised
$25M
Last Round
Series A — $14.4M (Jun 2026) · Lead: Astellas Venture Management
IPO Status
private

Fundraising Status

Series A · $14.4M · 3 mo ago
privateTotal raised $25M1 disclosed rounds

Funding History

RoundAmountDateLead InvestorPost-Money
Series A$14.4MJun 2026Astellas Venture Management—

Vertical Intelligence — Biotech / Gene Therapy

No name-verified sponsor record on ClinicalTrials.gov for Syntax Bio — trials may run under a different legal entity, a partner sponsor, or not yet exist. Absence of a registry match is reported as-is, never guessed around.
Checked clinicaltrials.gov as of 2026-09-19. Re-checked weekly.

Talent Signal

No public careers page or job board could be found for Syntax Bio as of 2026-09-14. That itself is a datapoint: no open external hiring surface.
Checked the company site and major hosted job boards. Re-checked monthly.

Founders & Key People

Doug DoerflerPete Bodine

Investors

Astellas Venture Management · Illumina Ventures · DCVC Bio · Civilization Ventures · EGB Capital · Mansueto Office · Portal Innovations · Draper Associates · Allegis Capital · LongGame · Mayo Clinic · Illinois Ventures
BiotechnologySynthetic BiologyRecently Funded
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of recent date. Refreshed quarterly.